Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 mg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to b-lactam antibiotics. Furthermore, among b -lactam antibiotics, the activity of carbapenems was most remarkably poteintiated by cyslabdan.Keywords cyslabdan, imipenem potentiator, methicillin-resistant Staphylococcus aureus, MRSA, Streptomyces sp. K04-0144, b-lactam
IntroductionDuring our screening for potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA) from microbial metabolites, cyslabdan ( Fig. 1) was isolated from the culture broth of Streptomyces sp. K04-0144. The compound has a labdane-type diterpene skeleton connecting with an N-acetylcysteine via thioether linkage [1]. In this study, the biological activities of cyslabdan including potentiation of imipenem activity against MRSA are described.
Materials and Methods
MaterialsThe following materials were purchased from commercial sources: Cloxacillin (ICN Biomedicals), ampicillin (Wako), cefalexin (Wako), cefazolin (Wako), ciprofloxacin (Wako), vancomycin (Wako), tetracycline (Wako), biapenem (Meiji Seika), streptomycin (Meiji Seika), meropenem (Sumitomo Pharmaceuticals), panipenem (Sankyo), penicillin G (Sigma), cefotaxime (Sigma), cefmetazole (Sigma), and imipenem (Banyu Pharmaceutical).
Microorganisms